Posted: Friday, October 31, 2025
Samuel M. Rubinstein, MD, discusses initial results from the bortezomib cohort of the multicohort LINKER-MM2 trial, which explored the combination of the T-cell–redirecting B-cell maturation antigen × CD3 bispecific antibody linvoseltamab and the proteasome inhibitor in heavily pretreated patients with multiple myeloma (EHA 2025 Abstract PS1716).
Resources
For your Patients
